Tislelizumab Plus Chemotherapy for Advanced Nsq-NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial
J Thorac Oncol 2021 May 22;[EPub Ahead of Print], S Lu, J Wang, Y Yu, X Yu, Y Hu, X Ai, Z Ma, X Li, W Zhuang, Y Liu, W Li, J Cui, D Wang, W Liao, J Zhou, Z Wang, Y Sun, X Qiu, J Gao, Y Bao, L Liang, M WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.